Targeting Novel Forms of Amyloid to Improve Upon the Current Standard of Care & Reduce Implications of ARIA
Time: 1:30 pm
day: Conference Day One - Track Three
Details:
- Outlining the promise of sabirnetug as a next generation treatment for AD
- Demonstrating significant reductions in ARIA-E and biomarker-driven signals of efficacy
- Implications for the future development of sabirnetug
